[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338085-105":59,"doc-detail-338085-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-claudin-182-for-cancer-therapy-updates-from-2024-asco-annual-meeting","Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting","","Multiple classes of therapies targeting claudin-18 isoform 2 (CLDN18.2) are in development for advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 ASCO Annual Meeting, final SPOTLIGHT phase 3 results showed a survival benefit from adding the CLDN18.2-specific antibody zolbetuximab to chemotherapy in the first line for tumors with ≥75% CLDN18.2 expression. Early phase data highlighted promising efficacy and safety for afucosylated FG-M108 plus chemotherapy, and additional ASCO 2024 trials explored ADCs, bispecific antibodies, and CAR-T strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-claudin-182-for-cancer-therapy-updates-from-2024-asco-annual-meeting/338085/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-claudin-182-for-cancer-therapy-updates-from-2024-asco-annual-meeting/338085.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What did the 2024 ASCO Annual Meeting report for zolbetuximab in first-line treatment?","Question",{"text":112,"@type":113},"Final SPOTLIGHT phase 3 results showed that adding zolbetuximab to chemotherapy improved survival outcomes in advanced gastroesophageal adenocarcinoma with ≥75% CLDN18.2 expression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is FG-M108 and what did early-phase ASCO 2024 data suggest?",{"text":117,"@type":113},"FG-M108 is an afucosylated CLDN18.2-specific antibody designed to enhance antibody-dependent cellular cytotoxicity. Early-phase results presented at ASCO 2024 showed promising efficacy and safety when combined with chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"Which other CLDN18.2-targeting strategies were presented at ASCO 2024 besides antibodies?",{"text":121,"@type":113},"ASCO 2024 presentations included other CLDN18.2-targeting approaches such as antibody–drug conjugates (LM-302, IBI343), a bispecific anti-CLDN18.2/CD3 antibody (IBI38), and CAR-T therapy (satricabtagene autoleucel).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338085,1790143764,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":19,"preview_urls":144},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Zhou et al. Journal of Hematology & Oncology (2024) 17:73 [https://doi.org/10.1186/s13045-024-01595-w](https://doi.org/10.1186/s13045-024-01595-w)  \nJournal of Hematology & Oncology  \nCORRESPONDENCE Open Access  \nTargeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting  \nKatherine I. Zhou 1, John H. Strickler 1,2 and Hui Chen 1,2*  \nAbstract  \nMultiple classes of therapies targeting claudin-18 isoform 2 (CLDN18 . 2) are under development for the treatment of advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the final results of the phase 3 SPOTLIGHT trial were presented, demonstrating a significant survival benefit from the addition of the CLDN18 . 2-specific antibody zolbetuximab to chemotherapy in the first-line treatment of advanced gastroesophageal adenocarcinomas with ≥ 75% CLDN18 .2 expression. Earlyphase trial results presented at ASCO 2024 showed promising efficacy and safety of the afucosylated CLDN18 .2-specific antibody FG-M108 in combination with chemotherapy in the first-line treatment of CLDN18 . 2-positive advanced gastroesophageal and pancreatic cancers. In addition, several early-phase trials presented at ASCO 2024 investigate other CLDN18 . 2-targeting approaches in CLDN18 . 2-positive refractory advanced solid tumors, includingthe CLDN18 . 2-targeting antibody–drug conjugates LM-302 and IBI343, the bispecific anti-CLDN18 . 2/CD3 antibody IBI38, and the chimeric antigen receptor T cell therapy satricabtagene autoleucel. These novel approaches could potentially expand the benefit of CLDN18 . 2-targeting therapies to a broader range of tumor types and to tumors expressing lower levels of CLDN18 .2.  \nKeywords Claudin-18 . 2, Targeted therapies, Antibody therapies, Antibody–drug conjugates, Bispecific antibodies, Chimeric antigen receptor T cell therapy, Gastrointestinal cancers, Gastroesophageal adenocarcinoma  \n*Correspondence:  \nHui Chen  \n[hui.chen@duke.edu](hui.chen@duke.edu)  \n1Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, 27708 Durham, NC, USA  \n2Duke Cancer Institute, Duke University, 27708 Durham, NC, USA  \nTo the Editor:  \nClaudin-18 isoform 2 (CLDN18.2) is an emerging target in gastroesophageal adenocarcinoma and other solid tumors [1]. Here, we review some new developments in targeting claudin-18.2 from ASCO 2024.  \nZolbetuximabfor CLDN18.2-positive gastroesophageal adenocarcinoma  \nThe phase 3 SPOTLIGHT and GLOW trials demonstrated the efficacy of the CLDN18.2-specific antibody zolbetuximab with chemotherapy for the first-line treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinomas with ≥ 75% of tumor cells showing moderate-to-strong membranous CLDN18.2 expression [2, 3]. In the final analysis of SPOTLIGHT [4], PFS and OS remained significantly improved with  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-","cbCaivqP9nXL2SuW","https://ap.wps.com/l/cbCaivqP9nXL2SuW","pdf",772222,"English","# Abstract\n## Zolbetuximab for CLDN18.2-positive gastroesophageal adenocarcinoma\n## FG-M108 for CLDN18.2-positive gastroesophageal and pancreatic cancers\n## Novel therapeutic strategies for CLDN18.2-positive advanced solid tumors\n## Antibody–drug conjugates (ADCs)\n## Bispecific antibodies and CAR-T therapies","[{\"question\":\"What did the 2024 ASCO Annual Meeting report for zolbetuximab in first-line treatment?\",\"answer\":\"Final SPOTLIGHT phase 3 results showed that adding zolbetuximab to chemotherapy improved survival outcomes in advanced gastroesophageal adenocarcinoma with ≥75% CLDN18.2 expression.\"},{\"question\":\"What is FG-M108 and what did early-phase ASCO 2024 data suggest?\",\"answer\":\"FG-M108 is an afucosylated CLDN18.2-specific antibody designed to enhance antibody-dependent cellular cytotoxicity. Early-phase results presented at ASCO 2024 showed promising efficacy and safety when combined with chemotherapy.\"},{\"question\":\"Which other CLDN18.2-targeting strategies were presented at ASCO 2024 besides antibodies?\",\"answer\":\"ASCO 2024 presentations included other CLDN18.2-targeting approaches such as antibody–drug conjugates (LM-302, IBI343), a bispecific anti-CLDN18.2/CD3 antibody (IBI38), and CAR-T therapy (satricabtagene autoleucel).\"}]","Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting | PDF",1790021896,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03590562ea22b72672c4a29ca114481a.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f114007137d07e5883ab01def6873c15.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c9bb9bcad8653d31662b6fd3674201b.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52492a88b57619f822e0cba75544feee.webp",980,1306]